EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myocardial Ischemia and Cardioprotection: From Pathophysiology to Novel Therapeutic Targets

Michael I. Adenawoola, Alan J. Mouton, Mursalin Khan, Huaxiu Zeng, Martin E. Young, David E. Stec

International Journal of Molecular Sciences · 19.11.2026 · 27 (22) · 10395

DOI: 10.3390/ijms272210395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.11.2026. Verfasst von Michael I. Adenawoola und 5 weiteren Autor:innen. Die Arbeit nennt 245 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences of the National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ischemic heart disease remains the leading cause of death worldwide and is frequently complicated by myocardial ischemia–reperfusion (I/R) injury, which contributes substantially to infarct expansion, adverse ventricular remodeling, and heart failure. The pathophysiology of myocardial ischemia involves a complex interplay among energy depletion, intracellular acidosis, calcium overload, oxidative stress, mitochondrial dysfunction, and the activation of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death pathways. Endogenous cardioprotective mechanisms, including ischemic preconditioning, postconditioning, remote ischemic conditioning, heat shock proteins, bilirubin signaling, and mitochondrial quality-control pathways, have demonstrated potent infarct-limiting effects in experimental models. These protective responses are mediated through interconnected signaling networks which converge to preserve mitochondrial integrity, maintain calcium homeostasis, reduce oxidative stress, and enhance cell survival. In addition, innate and adaptive immune responses play critical roles in post-infarction repair and remodeling, although excessive and/or prolonged inflammation can exacerbate injury. Despite strong mechanistic evidence, the translation of cardioprotective therapies into clinical practice has been challenging due to comorbidities, patient heterogeneity, and the complexity of human disease. Emerging approaches, including mitochondrial-targeted antioxidants, cell-based therapies, anti-inflammatory interventions, ferroptosis inhibitors, and SGLT2 inhibitors, offer promising opportunities for developing effective, multifaceted cardioprotective strategies.

Förderung

  • National Institutes of Health, National Heart, Lung, and Blood Institute
  • National Institute of General Medical Sciences of the National Institutes of Health

Zitieren

APA

Adenawoola, M. I., Mouton, A. J., Khan, M., Zeng, H., Young, M. E., & Stec, D. E. (2026). Myocardial Ischemia and Cardioprotection: From Pathophysiology to Novel Therapeutic Targets. International Journal of Molecular Sciences, 27(22), 10395. https://doi.org/10.3390/ijms272210395

Vancouver

Adenawoola MI, Mouton AJ, Khan M, Zeng H, Young ME, Stec DE. Myocardial Ischemia and Cardioprotection: From Pathophysiology to Novel Therapeutic Targets. International Journal of Molecular Sciences. 2026;27(22):10395. doi:10.3390/ijms272210395

BibTeX
@article{Adenawoola2026,
  author = {Adenawoola, Michael I. and Mouton, Alan J. and Khan, Mursalin and Zeng, Huaxiu and Young, Martin E. and Stec, David E.},
  title = {Myocardial Ischemia and Cardioprotection: From Pathophysiology to Novel Therapeutic Targets},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10395},
  doi = {10.3390/ijms272210395}
}
Kostenlos starten →